Reducing the Turnaround Time of the workflow for EGFR mutation test for NSCLC

The analysis is the result of collaboration between a hospital, a lab and hict.


The objective of the study was:

  • to evaluate the workflow, starting from “requesting and testing of EGFR mutations in non-small-cell lung carcinoma” to the “delivery of the results.”
  • to attempt to reduce the Turnaround Time (TAT) of the process to a run time of less than or equal to 10 days, which is the time proposed by the European consensus for EGFR mutation tests.

The results of this case will be used in a workshop with other hospitals as well, which will motivate these hospitals to also think about improving their workflow and possibly implement such improvements.


hict approached this project with the principles of ‘lean management’. Lean management is a way of thinking and acting throughout all levels of the organisation. Its starting point is described by what the customer wants and the resources needed.

Data analysis, interviews and observations are the techniques used to gather input.

hict also provided solutions to take on more efficiently those steps in the process that lead to long waiting periods or risks of errors.

The objective of such improvement programs is always to facilitate the doctor and the patient, to whom the timing is of the upmost importance, by giving them the results in a professional, fast, efficient and effective manner.


  • The steps in the process that create added value en those that might form obstacles were defined.
  • Solutions to these obstacles were defined which lead to a Turnaround Time reduced by 30% to 50%.
  • Awareness was created on everyone’s tasks in the process and on the effects of not delivering the results fast and of insufficiently communicating.
  • The information throughput between stakeholders is better due to improved communication. Every important step in the process is being communicated.
  • A solid partnership between the hospital and the lab has been set up.
  • The results of the EGFR mutation test are being delivered more quickly.
  • All of this resulted in starting the correct treatment faster for patients with NSLC and EFGR mutation.


Your contact person

Ann Tanghe
Senior Manager
Ann Tanghe
By submitting this form, you accept the Mollom privacy policy.
MeetDistrict | Ottergemsesteenweg-Zuid 808 B/354 | 9000 Gent | Belgium | Phone: +32 (0)92 77 77 84 | BTW BE 0866 039 556 | RPR/RPM Brugge | e-mail: